Not all patients with CLL require therapy. Even with all latest advances, the iwCLL nonetheless endorses watchful observation for people with asymptomatic disorder.86 This recommendation is based on a minimum of two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,10